Heron Capital
Heron Capital Equity Partners is a private equity firm based in Indianapolis, Indiana, specializing in investments in small to middle market companies. The firm focuses on buyouts, recapitalizations, and growth-stage companies, primarily within the life sciences, precision manufacturing, and healthcare sectors. Heron Capital seeks to invest in private companies located within 250 miles of Indianapolis, with total revenues of at least $2 million and earnings between $0.5 million and $4 million. The firm typically makes equity investments ranging from $1 million to $10 million and aims to acquire a controlling interest in its portfolio companies, preferring those that can achieve gross margins of over 35%. Heron Capital does not invest in retail and has a long-term investment approach, often taking a board seat in its portfolio companies. The firm operates an additional office in Carmel, Indiana, and leverages a network of scientists, physicians, and industry leaders to identify promising investment opportunities.
NeoChord, Inc. is a medical technology company that specializes in developing devices to address degenerative mitral valve disease (DMR), a condition that can lead to serious complications such as atrial fibrillation and congestive heart failure. The company's flagship product is the NeoChord Artificial Chordae Delivery System, a disposable device designed to repair damaged heart chordae through a small incision while the heart continues to beat. This innovative approach allows for mitral valve repair to be performed via a 2 to 3-inch incision between the ribs, significantly less invasive than traditional methods that require larger incisions and the use of heart-lung machines. Founded in 2007, NeoChord is headquartered in St. Louis Park, Minnesota.
AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implants that are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant.
Scale Computing, Inc. specializes in edge computing, virtualization, and hyperconverged solutions tailored for midsized businesses. Founded in 2007 and headquartered in Indianapolis, Indiana, the company offers its HC3™ platform, which integrates servers, storage, and virtualization into a single, user-friendly system. This all-in-one appliance enhances storage speed and capacity while simplifying datacenter management. HC3 continuously monitors virtual machines and hardware components to ensure application availability and efficiently address infrastructure events. In addition to its core platform, Scale Computing provides services such as infrastructure refresh, virtual-to-virtual migration, physical-to-virtual migration, and disaster recovery solutions. As a result, the company is increasingly favored by IT departments across various industries looking to maintain high availability and scalability of their applications.
AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implants that are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant.
AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implants that are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant.
Celleration Inc. develops and commercializes therapeutic ultrasound healing technologies in the United States. It offers MIST Therapy, a noncontact and low frequency ultrasound solution delivered through a saline mist to the wound bed. The company serves patients, medical professionals, and payers. Celleration Inc. was formerly known as Advanced Medical Applications, Inc. The company was founded in 1999 and is based in Eden Prairie, Minnesota. As of May 29, 2015, Celleration, Inc. operates as a subsidiary of Alliqua BioMedical, Inc.
IDEV Technologies is an emerging growth medical device company focused on the development of products for endovascular and interventional applications. Currently, IDEV markets SUPERA, a novel self-expanding nitinol stent. Using a patented interwoven design, SUPERA offers improved flexibility, radial strength, and kink and crush resistance compared to other marketed stents. SUPERA is currently approved for use in the treatment of biliary strictures in the US. IDEV is currently enrolling patients in the SUPERB IDE trial to study SUPERA's safety and efficacy when used in the superficial femoral artery (SFA).
Celleration Inc. develops and commercializes therapeutic ultrasound healing technologies in the United States. It offers MIST Therapy, a noncontact and low frequency ultrasound solution delivered through a saline mist to the wound bed. The company serves patients, medical professionals, and payers. Celleration Inc. was formerly known as Advanced Medical Applications, Inc. The company was founded in 1999 and is based in Eden Prairie, Minnesota. As of May 29, 2015, Celleration, Inc. operates as a subsidiary of Alliqua BioMedical, Inc.
BioSET, Inc., founded in 2001 and based in Rockville, Maryland, specializes in the research and development of synthetic bioactive peptides for medical applications. The company focuses on creating proprietary therapeutic peptides and implantable devices designed to enhance bone and soft tissue repair, particularly in orthobiologics. Its flagship product, Amplex, is an implantable device that combines a peptide with a synthetic ceramic scaffold, serving as a surgical bone graft implant for various spinal and orthopedic surgeries, including lumbar degenerative disc disease and foot and ankle fusion procedures. Additionally, BioSET develops products for sports medicine and offers peptide signaling molecules along with diverse scaffold biomaterials to support musculoskeletal applications, including trauma and fracture repair. As of February 2015, BioSET operates as a subsidiary of Ferring Pharmaceuticals Inc.
Atlantis Components specializes in the design and manufacturing of titanium abutments for dental implants. The company has developed a software system called the Virtual Abutment Design (VAD) system, which enables technicians to create abutments with unprecedented precision and certainty in the field of implant dentistry. Atlantis Components' designs are informed by extensive dental research and clinical input, allowing dentists to effectively restore implants using crown-and-bridge techniques. The consistent application of the VAD system ensures high-quality outcomes for both single and multiple unit cases, positioning Atlantis Components as a leader in dental implant solutions.
AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implants that are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant.
AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implants that are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.